We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.13 | -0.46% | 28.15 | 28.08 | 28.22 | 28.49 | 27.81 | 28.345 | 232,091 | 22:50:04 |
From May 2019 to May 2024
By Neetha Mahadevan
FRANKFURT--German pharmaceutical company Bayer AG said Thursday it is suspending enrollment into a Phase III trial for its Regorafenib drug for the treatment of colorectal cancer patients due to insufficient patient recruitment.
Regorafenib, also known as Stivarga, was to have been examined for the treatment of colorectal cancer patients following resection of liver metastases. It has already been approved in various countries, including the U.S., Europe and Japan, for the treatment of metastatic colorectal cancer, as well as to treat patients with gastrointestinal stromal tumors.
The study will be closed to further enrolment before the study endpoints can be assessed, Bayer said.
Regorafenib is a compound developed by Bayer and has an agreement with Onyx Pharmaceuticals Inc., an Amgen subsidiary, under which Onyx receives a royalty on all global net sales of regorafenib in oncology.
Write to Neetha Mahadevan at Neetha.Mahadevan@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
